Gunderson Dettmer represented client OrbiMed, a global healthcare investment firm, in closing more than $4.3 billion in capital commitments for its latest private investment funds. The new capital was raised across four funds with just over $1.86 billion for OrbiMed Private Investments IX, $1.71 billion for OrbiMed Royalty and Credit Opportunities IV and OrbiMed Royalty and Credit Opportunities IV Offshore, and $751 million for OrbiMed Asia Partners V.

OrbiMed focuses on innovative and growth-oriented opportunities across healthcare sub-sectors, including biopharmaceuticals, medical devices, diagnostics, and technology-enabled healthcare services. OrbiMed’s latest venture and royalty-and-credit funds are its largest ever.

In the announcement of the fund formations, Carter Neild, a Managing Partner of OrbiMed, stated that “OrbiMed is deeply appreciative of the continued support we’ve received from many long-standing partners who’ve invested in these funds. We will endeavor to meet our partners’ high expectations in the coming years.”

The Gunderson Dettmer deal team was led by Tyler Kirtley and Malcolm Nicholls, with assistance from Brian Huber, Joe Chase-Fielding, Sarah Anischik, Luke Charette and Tina Xu.

Companies
OrbiMed